PT  - JOURNAL ARTICLE
AU  - Cunningham, Muriel
ED  - Michaud, Kaleb
TI  - Higher Incremental Cost-Effectiveness Ratios Seen with Biologics in the TEAR Trial
DP  - 2013 Feb 01
TA  - MD Conference Express
PG  - 18--19
VI  - 13
IP  - 18
4099  - http://mdc.sagepub.com/content/13/18/18.short
4100  - http://mdc.sagepub.com/content/13/18/18.full
AB  - As additional treatments have been approved for rheumatoid arthritis (RA), researchers have used clinical trial data to analyze the cost effectiveness of these new drugs. Since 1998, more than 30 cost-effectiveness analyses (CEAs) have been conducted, with highly variable results. This article presents the CEA results of patient-level data from the Treatment of Early Aggressive Rheumatoid Arthritis trial [TEAR; NCT00259610], a large, randomized, double-blind clinical study.